# J.B. Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/jbchepharm

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,408.9
- Change: +0.00%
- As of: 2026-09-23
- 1D return: +0.00%
- 5D return: +0.00%
- 1M return: +0.00%
- Latest complete quarter: fy26_q4

## Faxioms Analysis

_As of 2026-09-25_

### Technical Outlook

As of September 23, 2026, JBCHEPHARM is positioned near the lower end of its recent trading ranges across daily, weekly, and monthly timeframes, indicating a potential consolidation phase. The stock's current price of ₹2408.9 is +19.9% from its 20-day, 50-day, and 252-day range lows, suggesting it has not yet established a clear directional trend or strong momentum. The lack of significant return since the start of the year and year-to-date suggests a period of sideways movement or limited price appreciation.

Participation and risk metrics are not detailed in the provided evidence. The immediate risk is a potential decline towards the lower bounds of its range, while upside confirmation would require a decisive move above key resistance levels. The conditions that would confirm or invalidate the current setup are not explicitly defined by the provided data.

- Stock is positioned near the lower end of its recent trading ranges across multiple timeframes.
- Current price of ₹2408.9 is +19.9% from 20-day, 50-day, and 252-day range lows.
- No significant return year-to-date or since the start of the year.
- Confirmation of an upward move would require breaking above key resistance levels, while a decline towards range lows represents immediate risk.
- Conditions for confirming or invalidating the current setup are not explicitly defined by the provided data.

### News Context

J. B. Chemicals & Pharmaceuticals Limited has officially been amalgamated with and dissolved into Torrent Pharmaceuticals Limited, effective July 8, 2026. This significant corporate action follows the sanction of the Scheme of Amalgamation by the National Company Law Tribunal (NCLT) on July 6, 2026, with the certified order received on July 7, 2026. The final filings with the Registrar of Companies, Ahmedabad, were completed on July 8, 2026. As part of the amalgamation, a record date of July 17, 2026, was set to determine shareholder entitlements. Shareholders of J. B. Chemicals & Pharmaceuticals will receive 51 Torrent Pharmaceuticals Limited shares for every 100 shares they held, based on the approved scheme. Separately, the company received confirmation on July 7, 2026, regarding compliance with SEBI regulations for the quarter ended June 30, 2026, pertaining to the dematerialization of securities.

- Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited became effective on July 8, 2026.
- The National Company Law Tribunal (NCLT) sanctioned the amalgamation scheme on July 6, 2026.
- Record date for amalgamation entitlement set as July 17, 2026.
- Shareholders to receive 51 Torrent Pharma shares for every 100 J. B. Chemicals shares held.
- Confirmation of SEBI Regulation 74(5) compliance received on July 7, 2026, for the quarter ended June 30, 2026.

### Official Filings

J. B. Chemicals & Pharmaceuticals Limited has been amalgamated with and dissolved into Torrent Pharmaceuticals Limited, effective July 8, 2026. This follows the National Company Law Tribunal's (NCLT) sanction of the amalgamation scheme on July 6, 2026, with the certified order received on July 7, 2026. The effective date of the amalgamation was confirmed by the filing of the certified order and scheme with the Registrar of Companies, Ahmedabad, on July 8, 2026. As part of the amalgamation, a record date of July 17, 2026, was set to determine shareholders entitled to receive Torrent Pharmaceuticals Limited shares. Shareholders are to receive 51 Torrent Pharma shares for every 100 J. B. Chemicals shares held. In other developments, the company's 50th Annual General Meeting on June 17, 2026, saw shareholders approve resolutions including the adoption of financial statements for the year ended March 31, 2026, and dividends totaling Rs. 22 per share (Rs. 12.70 interim and Rs. 9.30 final). The company also disclosed the retirement of two senior management personnel, Mr. Pradeep Kumar Singh and Mr. Suresh Bhise, effective June 30, 2026, and the resignation of Mr. Bhushan Sachdev from his position as Executive Vice President – Supply Chain Management, effective June 12, 2026.

- Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited became effective on July 8, 2026.
- Shareholders will receive 51 Torrent Pharma shares for every 100 J. B. Chemicals shares held.
- Record date for share entitlement under amalgamation was July 17, 2026.
- Shareholders approved total dividends of Rs. 22 per share at the 50th AGM on June 17, 2026.
- Two senior management personnel retired effective June 30, 2026, and one Executive Vice President resigned effective June 12, 2026.

- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_08072026113021_JB_SE_Intimation_Effective_Date.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_08072026113021_JB_SE_Intimation_Effective_Date.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026195932_SE_intimation_Record_date_for_Amalgamation.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026195932_SE_intimation_Record_date_for_Amalgamation.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026180222_SE_Intimation_Certified_copy_of_Order.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026180222_SE_Intimation_Certified_copy_of_Order.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026211912_SE_Intimation_Quarterly_Reg_74.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026211912_SE_Intimation_Quarterly_Reg_74.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_06072026184738_SE_Intimation_Pronuncement_of_Order_v1.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_06072026184738_SE_Intimation_Pronuncement_of_Order_v1.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026180436_NSE_retirement30062026.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026180436_NSE_retirement30062026.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026182058_NSE_TW30062026.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026182058_NSE_TW30062026.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026202753_Voting_Result_with_Scrutinizer_Report_Signed.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026202753_Voting_Result_with_Scrutinizer_Report_Signed.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026201352_Stock_exchange_proceeding.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026201352_Stock_exchange_proceeding.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_15062026175443_NSE_Bhushan_resignation_with_reason.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_15062026175443_NSE_Bhushan_resignation_with_reason.pdf)

### Fundamentals

J.B. Chemicals & Pharmaceuticals reported a sequential decrease in revenue from operations for Q4 FY2025-26, which stood at ₹904.23 crore compared to ₹1,064.72 crore in Q3 FY2025-26. This revenue decline was accompanied by a significant drop in profitability. Profit Before Tax fell to ₹134.69 crore in Q4 FY2025-26 from ₹266.87 crore in the prior quarter. The company also recorded exceptional items before tax of -₹27.18 crore in the latest quarter, which were absent in the preceding one. This resulted in a weaker profit conversion from revenue on a sequential basis.

Operating expenses, specifically Other Expenses, also saw a sequential decrease, coming in at ₹230.12 crore in Q4 FY2025-26 compared to ₹248.05 crore in Q3 FY2025-26. Finance costs also reduced sequentially from ₹1.88 crore to ₹1.23 crore. Despite these cost reductions, the substantial decline in revenue and the impact of exceptional items led to a lower overall profit for the quarter.

- Revenue from operations decreased sequentially to ₹904.23 crore in Q4 FY2025-26.
- Profit Before Tax declined significantly to ₹134.69 crore in Q4 FY2025-26 from ₹266.87 crore in Q3 FY2025-26.
- Exceptional items before tax were -₹27.18 crore in Q4 FY2025-26, impacting profitability.
- The next checkpoint is to monitor revenue trends and profit margins in the upcoming reporting period.

### FAQs

**What is the current status of J.B. Chemicals & Pharmaceuticals Limited following the amalgamation with Torrent Pharmaceuticals Limited?**

J.B. Chemicals & Pharmaceuticals Limited was amalgamated with and dissolved into Torrent Pharmaceuticals Limited, effective from January 21, 2026. The National Company Law Tribunal (NCLT) sanctioned the Scheme of Amalgamation on July 6, 2026, with the certified order received on July 7, 2026. The company was officially dissolved on July 8, 2026, after filing the certified copies of the order and scheme with the Registrar of Companies, Ahmedabad.

**How will J.B. Chemicals & Pharmaceuticals Limited shareholders be compensated following the amalgamation?**

J.B. Chemicals & Pharmaceuticals Limited shareholders are entitled to receive Torrent Pharmaceuticals Limited shares. The record date to determine eligible shareholders was set as July 17, 2026. According to the approved amalgamation scheme, shareholders will receive 51 Torrent Pharma shares for every 100 J. B. Chemicals shares held. Torrent Pharma shares have a face value of ₹5 each, while J. B. Chemicals shares had a face value of ₹1 each.

**What was the closing price and market capitalization of J.B. Chemicals & Pharmaceuticals Limited as of September 23, 2026?**

As of September 23, 2026, the closing price for J.B. Chemicals & Pharmaceuticals Limited was ₹2,408.9. The market capitalization on this date was ₹386,769,866,883.4.

- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_08072026113021_JB_SE_Intimation_Effective_Date.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_08072026113021_JB_SE_Intimation_Effective_Date.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026195932_SE_intimation_Record_date_for_Amalgamation.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026195932_SE_intimation_Record_date_for_Amalgamation.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026180222_SE_Intimation_Certified_copy_of_Order.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026180222_SE_Intimation_Certified_copy_of_Order.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026211912_SE_Intimation_Quarterly_Reg_74.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026211912_SE_Intimation_Quarterly_Reg_74.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_06072026184738_SE_Intimation_Pronuncement_of_Order_v1.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_06072026184738_SE_Intimation_Pronuncement_of_Order_v1.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026180436_NSE_retirement30062026.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026180436_NSE_retirement30062026.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026182058_NSE_TW30062026.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026182058_NSE_TW30062026.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026202753_Voting_Result_with_Scrutinizer_Report_Signed.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026202753_Voting_Result_with_Scrutinizer_Report_Signed.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026201352_Stock_exchange_proceeding.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026201352_Stock_exchange_proceeding.pdf)
- [https://nsearchives.nseindia.com/corporate/JBCHEPHARM_15062026175443_NSE_Bhushan_resignation_with_reason.pdf](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_15062026175443_NSE_Bhushan_resignation_with_reason.pdf)
## Technical analytics

- As of: 2026-09-23
- Daily trend: Insufficient History
- Weekly trend: Insufficient History
- Pivot point: —
- Risk regime: Not Enough History To Assess Price Risk

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_since_start | +0.00% |
| return_ytd | +0.00% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | insufficient_history |
| label | Not enough history to assess price risk |
| summary | There is not enough history to make a reliable risk assessment. |
| maximum_drawdown | +0.00% |

## Quarterly financials

- Latest complete quarter: fy26_q4

# Revenue and Profitability Contract as Expenses Outpace Sales Decline

J.B. Chemicals & Pharmaceuticals reported a contraction in both sales and earnings for the quarter ended March 2026. Revenue fell 4.8% compared to the same period last year and dropped 15.1% from the preceding quarter. Profit before tax declined more sharply, falling 30.2% year-on-year and 49.5% sequentially, driven by a slower reduction in operating costs and a reported exceptional charge.

## Revenue and Profitability Trends

Revenue from operations totaled ₹904.23 crore in the fourth quarter, down from ₹949.48 crore a year earlier and ₹1,064.72 crore in the third quarter. Over the fiscal year, sales peaked at ₹1,093.94 crore in the first quarter and trended downward through the second and third quarters before the steeper decline in the final quarter.

Profit before exceptional items and tax (PBEIT) followed a similar path, settling at ₹161.87 crore. This represents a 16.1% decrease from the prior-year quarter and a 39.3% drop from the previous quarter. As a percentage of revenue, PBEIT margin compressed from 20.3% a year ago and 25.1% in the third quarter to 17.9% in the current quarter. The wider drop in profit compared to revenue indicates that operating costs did not scale down proportionally with the sales decline.

## Impact of Exceptional Items

Pre-tax profit (PBT) closed at ₹134.69 crore, reflecting a 30.2% year-on-year decline and a 49.5% sequential fall. The reported results include an exceptional item before tax of –₹27.18 crore for the quarter, which was not present in the four preceding quarters. This charge accounted for roughly one-fifth of the sequential drop in pre-tax profit, with the remainder stemming from the lower underlying operating profitability.

## Expense Composition

Total operating expenses came to ₹754.34 crore, a 2.2% decrease year-on-year and a 7.6% decrease from the third quarter. While expenses declined, the pace of reduction lagged behind the double-digit sequential drop in revenue.

Key expense components for the quarter include:
- Cost of materials consumed: ₹233.71 crore
- Purchases of stock-in-trade: ₹102.82 crore
- Change in inventories: –₹62.28 crore
- Employee benefit expense: ₹198.73 crore
- Depreciation, depletion, and amortisation: ₹50.01 crore
- Finance costs: ₹1.23 crore
- Other expenses: ₹230.12 crore

Employee benefits and other expenses combined made up 56.8% of total costs. Both categories showed limited responsiveness to the revenue contraction; other expenses actually rose 2.5% year-on-year to ₹230.12 crore despite lower sales.

## Capital Structure

Paid-up equity share capital increased to ₹16.06 crore at the end of the quarter, up from ₹15.57 crore a year earlier. The face value of shares remained unchanged at ₹1 per share.

## Key Takeaway

The quarter concluded with a notable pullback in sales and earnings. Profitability contracted more steeply than revenue because operating expenses, particularly employee costs and general overheads, decreased at a slower rate. An additional exceptional charge further weighed on pre-tax results. The performance marks a clear deceleration from the higher revenue and profit levels recorded in the first three quarters of the fiscal year.

### Ratios

## Shareholding pattern

- Quarter: FY2026-Q4
- As of: 2026-03-31
- Promoter holding: +48.80%
- FII holding: +16.33%
- DII holding: +21.38%
- Mutual fund holding: +19.00%
- Retail holding: +11.04%
- Promoter pledged: +0.00%

### Major reported shareholders

- TORRENT PHARMACEUTICALS LIMITED — +48.80% (Bodies Corporate)
- KOTAK MIDCAP FUND — +4.40%
- AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL FUND A/C AXIS SMALL CAP FUND — +3.81%
- CANARA ROBECO MUTUAL FUND A/C CANARA ROBECO SMALL CAP FUND — +2.17%
- GOVERNMENT PENSION FUND GLOBAL — +1.84%
- NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHARMA FUND — +1.60%
- SMALLCAP WORLD FUND, INC — +1.30%
- FRANKLIN INDIA SMALL CAP FUND — +1.26%

## Official filings

- 2026-07-08 — Generic Announcement: On July 8, 2026, J. B. Chemicals & Pharmaceuticals Limited (JB Chemicals) was amalgamated with and dissolved into Torrent Pharmaceuticals Limited, effective from the Appointed Date of January 21, 2026. This follows the approval and sanction of the Scheme of Amalgamation by the National Company Law Tribunal (NCLT) on July 6, 2026, with the certified order received on July 7, 2026. The certified copies of the order and scheme were filed with the Registrar of Companies, Ahmedabad, on July 8, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_08072026113021_JB_SE_Intimation_Effective_Date.pdf)
- 2026-07-07 — Generic Announcement: J. B. Chemicals & Pharmaceuticals Limited has fixed July 17, 2026, as the record date to determine shareholders entitled to receive Torrent Pharmaceuticals Limited shares as per the approved amalgamation scheme. Shareholders will receive 51 Torrent Pharma shares for every 100 J. B. Chemicals shares held, with Torrent Pharma shares having a face value of Rs. 5 each and J. B. Chemicals shares having a face value of Re. 1 each. This follows the National Company Law Tribunal's order dated July 6, 2026, sanctioning the amalgamation. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026195932_SE_intimation_Record_date_for_Amalgamation.pdf)
- 2026-07-07 — Generic Announcement: The National Company Law Tribunal, Ahmedabad Bench, sanctioned the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited on July 6, 2026. J. B. Chemicals & Pharmaceuticals Limited received the certified true copy of this order on July 7, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026180222_SE_Intimation_Certified_copy_of_Order.pdf)
- 2026-07-07 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited received a certificate from its Registrar and Share Transfer Agents, Datamatics Business Solutions Limited, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This certificate covers the quarter ended June 30, 2026, and verifies that securities received for dematerialization were mutilated, cancelled, and replaced with the depository as the registered owner within 15 days of receipt. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026211912_SE_Intimation_Quarterly_Reg_74.pdf)
- 2026-07-06 — Generic Announcement: The Hon'ble National Company Law Tribunal, Ahmedabad Bench, has sanctioned the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited. The sanction was granted via an order dated July 6, 2026. The Scheme will become effective upon filing the certified copy of the order with the Registrar of Companies. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_06072026184738_SE_Intimation_Pronuncement_of_Order_v1.pdf)
- 2026-06-30 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited announced the retirement of two senior management personnel, Mr. Pradeep Kumar Singh (President Global Business) and Mr. Suresh Bhise (Vice President – IT), effective June 30, 2026. This disclosure is made in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026180436_NSE_retirement30062026.pdf)
- 2026-06-30 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited will close its trading window from July 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ending June 30, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026182058_NSE_TW30062026.pdf)
- 2026-06-17 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited held its 50th Annual General Meeting on June 17, 2026, through video conference. All resolutions, including the adoption of financial statements for the year ended March 31, 2026, confirmation of an interim dividend of Rs. 12.70 per share, declaration of a final dividend of Rs. 9.30 per share, and the re-appointment of Mr. Amal Kelshikar as a director, were approved by the shareholders with a significant majority. The voting results were based on consolidated reports from the appointed scrutinizer. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026202753_Voting_Result_with_Scrutinizer_Report_Signed.pdf)
- 2026-06-17 — Generic Announcement: The 50th Annual General Meeting of J. B. Chemicals & Pharmaceuticals Limited was held on June 17, 2026, via Video Conference. The meeting addressed four ordinary resolutions, and members participated through remote e-voting and an e-voting platform provided by CDSL. The Statutory Auditors' and Secretarial Audit Reports contained no adverse qualifications. The meeting concluded at 3:55 PM IST, with voting results to be announced separately. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026201352_Stock_exchange_proceeding.pdf)
- 2026-06-15 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited announced that Mr. Bhushan Sachdev has resigned from his position as Executive Vice President – Supply Chain Management due to personal reasons, effective June 12, 2026. This disclosure is made in compliance with SEBI regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_15062026175443_NSE_Bhushan_resignation_with_reason.pdf)
- 2026-06-13 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited submitted audited standalone and consolidated financial results for the fiscal year ended March 31, 2026, on May 11, 2026. The Board of Directors approved these results and authorized Director Mr. Sudhir Menon to sign them for submission to the stock exchanges. This clarification was provided in response to an email from the National Stock Exchange of India Limited dated May 20, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_21052026175045_Reply_to_NSE.pdf)
- 2026-06-12 — Management Change: Mr. Bhushan Sachdev has resigned as Executive Vice President – Supply Chain Management for J.B. Chemicals & Pharmaceuticals Limited, effective June 12, 2026. This disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_12062026181112_NSEIntimationCessationofSMP.pdf)
- 2026-05-27 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited dispatched letters on May 27, 2026, providing a web-link to access its Integrated Annual Report for FY 2025-26 to shareholders who have not registered their email addresses. The company also announced its 50th Annual General Meeting (AGM) scheduled for June 17, 2026, to be held via Video Conference (VC) / Other Audio-Visual Means (OAVM). The Notice of the 50th AGM and the Integrated Annual Report for FY 2025-26 were sent electronically to members with registered email addresses. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_27052026183403_NSE_Weblink25062026.pdf)
- 2026-05-26 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited published a notice on May 26, 2026, regarding its Annual General Meeting scheduled for June 17, 2026. The meeting will be conducted via Video Conferencing (VC)/Other Audio Visual Means (OAVM), in compliance with SEBI regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_26052026203843_NSE_newspaper_26052026.pdf)
- 2026-05-25 — Generic Announcement: J. B. Chemicals & Pharmaceuticals Limited will hold its 50th Annual General Meeting on June 17, 2026, via video conference. The agenda includes adopting financial statements for the year ended March 31, 2026, confirming an interim dividend of ₹12.70 per equity share, declaring a final dividend of ₹9.30 per equity share for the 2025-26 financial year, and re-appointing Mr. Amal Kelshikar as a director retiring by rotation. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_25052026170303_NSE_Notice2026.pdf)
- 2026-05-25 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited has submitted its Business Responsibility and Sustainability Report for the financial year 2025-26, as required by SEBI regulations. The report details the company's performance and commitments across environmental, social, and governance (ESG) pillars. Key disclosures include operational data, employee welfare initiatives, and progress towards sustainability goals such as renewable energy adoption and carbon neutrality targets. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_25052026183655_NSE_BRSR2026.pdf)
- 2026-05-21 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited has fixed May 29, 2026, as the record date to determine shareholder eligibility for the final dividend for the financial year 2025-26. This action is in accordance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_21052026183424_NSE_RecordDate.pdf)
- 2026-05-20 — Official Filing: J.B. Chemicals & Pharmaceuticals Limited will convene its Annual General Meeting on June 17, 2026, utilizing Video Conferencing (VC)/Other Audio Visual Means (OAVM). This disclosure, made on May 20, 2026, precedes the dispatch of the official AGM notice and the 2025-26 annual report to shareholders, adhering to Ministry of Corporate Affairs guidelines.
- 2026-05-13 — Official Filing: J.B. Chemicals & Pharmaceuticals Limited held an Investors/Analysts call on May 12, 2026, to discuss results for the fourth quarter ended March 31, 2026. The company reported revenue of INR904 crores, a 5% decrease, with INR40 crores in one-off charges. Adjusted EBITDA was flat at INR241 crores, and reported net profit after tax was INR101 crores, or INR150 crores adjusted for one-offs. The Board recommended a final dividend of INR9.3 per equity share. The merger with Torrent Pharma is in its final stages, with a hearing expected in June 2026.
- 2026-05-12 — Official Filing: J.B. Chemicals & Pharmaceuticals Limited published a newspaper advertisement on May 12, 2026, detailing its financial results for the quarter and financial year ended March 31, 2026. This disclosure was made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2026-05-12 — Official Filing: J.B. Chemicals & Pharmaceuticals Limited has made available the audio recording of an investor and analyst conference call held on May 12, 2026. The call pertained to the company's results and developments for the fourth quarter ended March 31, 2026. The recording is accessible on the company's website.
- 2026-05-11 — Official Filing: On May 11, 2026, J.B. Chemicals & Pharmaceuticals Limited disclosed that a company petition for the Scheme of Amalgamation with Torrent Pharmaceuticals Limited was admitted by the National Company Law Tribunal on May 7, 2026. The hearing for this petition is scheduled for June 11, 2026. Newspaper advertisements regarding this notice were published on May 11, 2026.
- 2026-05-11 — Official Filing: J.B. Chemicals & Pharmaceuticals Ltd. reported Q4 FY26 results with revenue at Rs. 904 crores and EBITDA at Rs. 241 crores, a 5% YoY decrease in revenue. The company experienced a net profit after tax of Rs. 101 crores, down 30% YoY. Performance was impacted by integration activities following a change of control, including distribution network optimization, discontinuation of low-margin products, and alignment of practices with the parent entity, affecting both domestic and international business segments. The company anticipates progressive performance improvement starting in Q1 FY27.
- 2026-05-11 — Official Filing: The Board of Directors of J.B. Chemicals & Pharmaceuticals Ltd. recommended a final dividend of Rs. 9.30 per equity share (930%) for the financial year 2025-26. This recommendation was made during a board meeting held on May 11, 2026. The dividend, if approved by shareholders at the Annual General Meeting, will be paid within 30 days of its declaration.
- 2026-05-11 — Official Filing: J. B. Chemicals & Pharmaceuticals Ltd. announced the audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The Board of Directors approved these results, which include an unmodified audit opinion from Deloitte Haskins & Sells LLP. The company also reported related party transactions for the half-year ending March 31, 2026. The proposed amalgamation scheme with Torrent Pharmaceuticals Limited received approval from shareholders on April 28, 2026, with an appointed date of January 21, 2026.

## News and market events

No recent news or market events are currently available.

## Business profile

**Strategic vision:** Manufactures and markets diverse pharmaceutical products globally.

### Business segments
- **Pharmaceutical Manufacturing and Marketing:** Engaged in the manufacturing and marketing of a diverse range of pharmaceutical products, including generic and branded generics across various therapeutic categories.

### Competitive strengths
- Extensive global distribution network across over 40 countries.
- Multiple world-class manufacturing facilities with numerous international accreditations.
- Broad therapeutic area coverage and diverse product dosage forms.

## Freshness and sources

- Data as of: 2026-09-23
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/jbchepharm
Markdown representation: https://faxioms.com/stocks/jbchepharm?render=md